Loading...
•
Jun 30, 2024
Castle Biosciences Q2 2024 Earnings Report
Revenue increased by 74% year-over-year, driven by growth in test report volumes across therapeutic areas and publication of study evaluating DecisionDx-SCC test.
Key Takeaways
Castle Biosciences reported a strong second quarter with a 74% increase in revenue compared to the same period last year. The company also raised its full-year revenue guidance to $275-300 million.
Revenues were $87.0 million, a 74% increase compared to Q2 2023.
Total test reports delivered increased by 49% compared to Q2 2023.
Net income was $8.9 million, compared to a net loss of $(18.8) million for the same period in 2023.
Company is raising full-year 2024 revenue guidance to $275-300 million.
Forward Guidance
The Company is increasing its guidance for anticipated total revenue in 2024 to between $275–300 million, compared to the previously provided guidance of between $255–265 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...